Art. -Nr.: HY-B2114

Escin

3 Cited Publications

Kundenbewertung

Based on 3 publication(s) in Google Scholar

Escin, a natural compound of triterpenoid saponins that can be isolated from horse chestnut (Aesculus hippocastanum) seeds, can be used as a vasoprotective anti-inflammatory, anti-edematous and anti-nociceptive agent.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 96.6%
CAS. Nr.: 6805-41-0
Formel: C₅₅H₈₆O₂₄
Molecular Weight:1131.25

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Escin Chemical Structure

CAS. Nr.: 6805-41-0

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (3)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

In Vitro

Escin (1 μM, 0-5 h) stimulates phosphorylation of the GR in CFTL-12 murine mast cells^[1].
Escin (0.1-1 µg/mL, 24 h) protects cells from OGD/R and rt-PA stimulaed cell damage in bEnd.3 cells^[2].
Escin (0-100 μg/mL, 12-48 h) induces cell cycle arrest and apoptosis, and inhibits tumor cell proliferation in HCT116 and HCT8 cells^[5].
Escin (0-80 μg/mL, 12-24 h) induces DNA damage, and upregulates p-ATM and γH2AX in HCT116 and HCT8 cells^[5].
Escin (0-50 μM, 24 h) decreases mitochondrial membrane potential and induces cytochrome C release via generation of ROS, and induces apoptosis of bladder cancer cells (T24 and J82 cells )^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:

OGD/R and rt-PA stimulated bEnd.3 cells
Concentration:

0.1, 0.5 and 1 µg/mL
Incubation Time:

24 h
Result:

Upregulated the expression of ZO-1 and Occludin.

In Vivo

Escin (1-5 mg/kg, p.o.) inhibits the allergic skin response in Porcine induced by Compound 48/80 (HY-115768)^[1].
Escin (0.5 and 1 mg/kg, i.v.) attenuates recombinant tissue plasminogen activator (rt-PA) induced hemorrhagic transformation (HT) in mice^[2].
Escin (10 mg/kg, p.o., 4 days) shows antioxidant, anti-inflammatory, antinecrotic, and anti-apoptotic effects against Con A-induced immune-mediated hepatitis in mice^[3].
Escin (5-20 mg/kg, p.o., once a day, after 6 weeks of diabetes induction, for next 4 weeks) alleviates peripheral neuropathy in Streptozotocin (HY-13753) induced diabetes in rats^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Con A-induced immune-mediated hepatitis mice^[3]
Dosage:

10 mg/kg
Administration:

p.o., 4 days
Result:

Decreased the peak activities of ALT (p < 0.01), AST (p < 0.001), and LDH.
Ameliorated hepatic pathological abnormalities.
Limited Con A-induced elevation in Ly6G-positive cell in liver.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 6805-41-0
Appearance Solid
Molecular Weight 1131.25
Formel C₅₅H₈₆O₂₄
Color White to yellow
SMILES

OC[C@]12[C@](CC(C)([C@H]([C@@H]2OC(C)=O)[R])C)([H])C3=CC[C@@]([C@@]4([C@@]([C@](C)([C@H](CC4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(O)=O)O[C@@H]6O[C@@H]([C@H]([C@@H]([C@H]6O)O)O)CO)O)O[C@@H]7O[C@@H]([C@H]([C@@H]([C@H]7O)O)O)CO)CO)([H])CC8)C)([H])[C@]8(C)[C@@]3(C[C@H]1O)C.CC(OC[C@]9%10[C@](CC(C)([C@H]([C@@H]%10O)[R])C)([H])C%11=CC[C@@]([C@@]%12([C@@]([C@](C)([C@H](CC%12)O[C@H]%13[C@@H]([C@H]([C@@H]([C@H](O%13)C(O)=O)O[C@@H]%14O[C@@H]([C@H]([C@@H]([C@H]%14O)O)O)CO)O)O[C@@H]%15O[C@@H]([C@H]([C@@H]([C@H]%15O)O)O)CO)CO)([H])CC%16)C)([H])[C@]%16(C)[C@@]%11(C[C@H]9O)C)=O.[O]C(/C(C)=C\C)=O.[O]C(/C(C)=C/C)=O.[O]C(/C(C)=C\C)=O.[O]C(/C(C)=C/C)=O.[Aescin A].[Aescin B].[(E)].[(Z)].[Aescin C].[Aescin D].[(Z)].[(E)]
Structure Classification
- Terpenoids
- Triterpenes
- Saccharides
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (3)

All Cell Proliferation/Viability AssayFlow Cytometry

Sort by:

Journal Impact Factor

Stem Cells Int

Escin Preincubation Enhances the Therapeutic Effect of Umbilical Cord-Derived Mesenchymal Stem Cells in a Rat Model of Myocardial Infarction. [Abstract]

2025 Nov 21:2025:1115668. PMID: 41323777

Escin purchased from MedChemExpress. Usage Cited in: Stem Cells Int. 2025 Nov 21:2025:1115668. [Abstract]

CCK-8 was used to detect the activity of UCMSCs after treatment with different concentrations of Escin (10, 20, 30, 40 μM) at 72 h.

Escin purchased from MedChemExpress. Usage Cited in: Stem Cells Int. 2025 Nov 21:2025:1115668. [Abstract]

Cell cycle distribution of UCMSCs after Escin treatment.
Res Sq

2024 Sep 05.
SSRN

21 Nov 2022.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (88.40 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.8840 mL

4.4199 mL

8.8398 mL

5 mM

0.1768 mL

0.8840 mL

1.7680 mL

10 mM

0.0884 mL

0.4420 mL

0.8840 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (4.42 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (293 KB)
SDS (563 KB)
- English - EN (563 KB)
- Français - FR (563 KB)
- Deutsch - DE (563 KB)
- Norwegian - NO (563 KB)
- Español - ES (563 KB)
- Swedish - SV (563 KB)
- Italian - IT (563 KB)
- Portuguese - PT (563 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Sipos W, et al. Escin inhibits type I allergic dermatitis in a novel porcine model. Int Arch Allergy Immunol. 2013;161(1):44-52. [Content Brief]

[2]. Sun X, et al. Escin avoids hemorrhagic transformation in ischemic stroke by protecting BBB through the AMPK/Cav-1/MMP-9 pathway. Phytomedicine. 2023 Nov;120:155071. [Content Brief]

[3]. Elshal M, Hazem SH. Escin suppresses immune cell infiltration and selectively modulates Nrf2/HO-1, TNF-α/JNK, and IL-22/STAT3 signaling pathways in concanavalin A-induced autoimmune hepatitis in mice. Inflammopharmacology. 2022 Dec;30(6):2317-2329. [Content Brief]

[4]. Suryavanshi SV, Kulkarni YA. Escin alleviates peripheral neuropathy in streptozotocin induced diabetes in rats. Life Sci. 2020 Aug 1;254:117777. [Content Brief]

[5]. Wang Z, et al. Escin-induced DNA damage promotes escin-induced apoptosis in human colorectal cancer cells via p62 regulation of the ATM/γH2AX pathway. Acta Pharmacol Sin. 2018 Oct;39(10):1645-1660. [Content Brief]

[6]. Cheng CL, et al. Escin induces apoptosis in human bladder cancer cells: An in vitro and in vivo study. Eur J Pharmacol. 2018 Dec 5;840:79-88. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	0.8840 mL	4.4199 mL	8.8398 mL	22.0994 mL
	5 mM	0.1768 mL	0.8840 mL	1.7680 mL	4.4199 mL
	10 mM	0.0884 mL	0.4420 mL	0.8840 mL	2.2099 mL
	15 mM	0.0589 mL	0.2947 mL	0.5893 mL	1.4733 mL
	20 mM	0.0442 mL	0.2210 mL	0.4420 mL	1.1050 mL
	25 mM	0.0354 mL	0.1768 mL	0.3536 mL	0.8840 mL
	30 mM	0.0295 mL	0.1473 mL	0.2947 mL	0.7366 mL
	40 mM	0.0221 mL	0.1105 mL	0.2210 mL	0.5525 mL
	50 mM	0.0177 mL	0.0884 mL	0.1768 mL	0.4420 mL
	60 mM	0.0147 mL	0.0737 mL	0.1473 mL	0.3683 mL
	80 mM	0.0110 mL	0.0552 mL	0.1105 mL	0.2762 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Escin

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Anti-diabetic Compound Library

Glycoside Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

FDA-Approved Anticancer Drug Library

Off-patent Drug Library

Cell Death Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Bioactive Compound Library Max

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Cosmetic Ingredient Compound Library

Mongolian Medicine Compound Library

Publications Citing Use of MedChemExpress (MCE) Escin

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Escin Related Classifications

Art. -Nr.: HY-B2114